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the assessment of bone metastasis as
add-on to planar bone scintigraphy:
prospective head-to-head comparison
to 11-min SPECT/CT
Helle D. Zacho1,2* , José A. Biurrun Manresa3,4, Ramune Aleksyniene1, June A. Ejlersen5, Joan Fledelius5,
Henrik Bertelsen1 and Lars J. Petersen1,2Abstract
Background: The aim of this study is to assess whether ultra-fast acquisition SPECT/CT (UF-SPECT/CT) can replace
standard SPECT/CT (std-SPECT/CT) as “add-on” to whole-body bone scintigraphy (WB-BS) for the investigation
of bone metastases.
Consecutive cancer patients referred for WB-BS who underwent SPECT/CT in addition to WB-BS were included.
Std-SPECT, UF-SPECT, and low-dose CT were performed (std-SPECT: matrix 128 × 128, zoom factor 1, 20 s/view, 32
views; UF-SPECT: identical parameters except for 10 s/view and 16 views, reducing the acquisition time from 11 to
3 min). A consensus diagnosis was reached by two observers for each set of images (WB-BS + standard SPECT/CT
or WB-BS + UF-SPECT/CT) using a three-category evaluation scale: M0: no bone metastases; M1: bone metastases;
and Me: equivocal findings.
Results: Among the 104 included patients, most presented with prostate cancer (n = 71) or breast cancer (n = 28).
Using WB-BS + std-SPECT/CT, 71 (68%) patients were classified as M0, 19 (18%) as M1, and 14 (14%) as Me.
Excellent agreement was observed between WB-BS + std-SPECT/CT and WB-BS + UF-SPECT/CT using the
three-category scale: kappa = 0.91 (95% CI 0.84–0.97). No difference in observer agreement between cancer
types was detected. SPECT/CT provided a definitive classification in 90 of 104 cases in which WB-BS was not
entirely diagnostic.
Conclusions: To investigate potential bone metastases, UF-SPECT/CT can be conducted as add-on to WB-BS
to notably reduce the SPECT acquisition time without compromising diagnostic confidence.
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Whole-body bone scintigraphy (WB-BS) is commonly
used to assess the involvement of the skeleton in various
cancers, such as prostate and breast cancer [1]. In pros-
tate cancer, WB-BS is the recommended investigation in
newly diagnosed patients, in patients with recurrent
disease and in patients receiving a treatment response
evaluation [2, 3]. The reported sensitivity of WB-BS in
diagnosing bone metastases is high, but its specificity is
moderate [4, 5].
Since the introduction of WB-BS, technical progress in
molecular imaging has emerged in the form of tomo-
graphic imaging combined with anatomical mapping, as
observed in single-photon emission computed tomog-
raphy (SPECT) combined with computed tomography
(CT) (SPECT/CT). In the last decade, SPECT/CT has
become widely available at nuclear medicine clinics in
Europe and in the USA [6]. Several studies have re-
ported improved diagnostic confidence when using
SPECT/CT as an “add-on” to WB-BS in cases of equivo-
cal or suspicious lesions, particularly due to the in-
creased specificity of SPECT/CT [4, 7–10]. In breast
cancer, SPECT/CT may also improve diagnostic sensitiv-
ity [4]. Nevertheless, the addition of SPECT/CT to WB-
BS is rather time-consuming and may prolong the exam-
ination time by 15–20 min for each bed position needed
[4, 7]. A long acquisition time may be a challenge in
terms of patient capacity and patient compliance; many
patients with pain may find it difficult to lie still for 30–
40 min for two-bed SPECT/CT. A short acquisition time
is technically attainable; however, the acquisition time
should not be reduced at the cost of compromised
diagnostic confidence.
The aim of the present prospective study was to
investigate whether ultra-fast acquisition SPECT/CT can
replace standard SPECT/CT without the compromising
diagnostic value.
Methods
Patients
One hundred and four patients of 503 patients referred
for BS at our department were enrolled in this prospect-
ive study from July 2014 to January 2015. The inclusion
criteria were as follows: (1) a diagnosis of cancer; (2) re-
ferral as part of a routine clinical bone scintigraphy
examination due to the suspicion of bone metastases; (3)
performance of SPECT/CT in accordance with institu-
tional practice as required by the nuclear medicine phys-
ician in charge as an add-on to WB-BS in cases of (a)
equivocal lesions on WB-BS or (b) patient complaints of
localized, cancer-suspicious pain despite normal WB-BS
findings; and (4) receipt of a signed consent form.
All patients filled out a standard questionnaire regarding
bone-related pain and known benign bone conditions thatmight impact the diagnostic classification of the bone
scintigraphy results, such as recent trauma, osteoarthritis,
or recent surgery to bones or joints.
Bone scintigraphy
WB-BS
Standard WB-BS was performed in accordance with the
European Society of Nuclear Medicine guidelines [11]. Tc-
99m-labeled methylene bisphosphonate (750–1000 MBq,
20–27 mCi) was injected 2 to 3 h before image acquisition.
The patients were orally hydrated, and they voided their
bladders immediately prior to undergoing WB-BS. Symbia
dual-head gamma cameras (Symbia T16, Siemens Medical
Solutions, Erlangen, Germany) capable of simultaneous an-
terior and posterior acquisition and equipped with multi-
purpose, low-energy, high-resolution collimators were
used. The scan speed was 24 cm/min, with alpha blending
of 30% [12], a matrix size of 256 × 1024, and a zoom factor
of 1. The WB-BS images were evaluated by the physician
in charge, who decided on the need for additional SPECT/
CT (as well as the number of bed positions).
SPECT
Standard SPECT (std-SPECT) was conducted using the
following parameters: matrix 128 × 128, zoom factor 1,
20 s per view, 32 views, rotation of the detectors by 180°
in a non-circular orbit, and step-and-shoot mode. Ultra-
fast acquisition SPECT (UF-SPECT) was conducted
using the same parameters as std-SPECT, except for 16
views of 10 s per view; thus, the effective acquisition
time was reduced from 11 min (10 min 40 s) for std-
SPECT to 3 min (2 min 40 s) for UF-SPECT. The total
camera time for SPECT was reduced from 13 min 20 s
to 4 min 50 s. Resolution recovery (Flash 3D) iterative
reconstruction (four iterations over eight subsets) with
scatter correction was used for both types of SPECT.
The parameters for UF-SPECT acquisition were chosen
based on an exploratory pilot study conducted before
initiating the present study.
CT
Low-dose CT was performed for attenuation correction
and anatomical co-registration using the following pa-
rameters: 25 mA, 130 peak keV, scan time 13.55 s, 30
mAs, and slice thickness 0.6 mm. Only one CT scan was
performed and used for both std-SPECT and UF-SPECT.
Images were fused using the manufacturer’s software
(e.soft™ application on the Symbia.net™ Clinical Work-
flow System, Siemens Healthcare, Erlangen, Germany).
Patients were allocated to one of two sequences accord-
ing to their date of birth: (1) std-SPECT, low-dose CT
followed by UF-SPECT, or (2) UF-SPECT, low-dose CT
followed by std-SPECT. WB-BS and std-SPECT/CT
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SPECT/CT were not used for clinical purposes).
Observers and procedure for image assessment
Four board-certified nuclear medicine physicians with
7–10 years of experience from two departments of nu-
clear medicine (Aalborg and Herning) evaluated the UF-
SPECT/CT and re-evaluated the std-SPECT/CT. All of
the observers were experienced with std-SPECT/CT.
The observers had access to the clinical data provided
by the referring physician and to the bone-related ques-
tionnaire responses. They had no access to the previous
imaging data or to the clinical report of the WB-BS +
std-SPECT/CT findings. The observers from Herning
had approximately 1 year of clinical experience with
UF-SPECT/CT in selected patients. In contrast, the
observers from Aalborg had no experience with UF-
SPECT/CT.
The images for each patient were examined by two ob-
servers, one from each department. The WB-BS + std-
SPECT/CT or WB-BS + UF-SPECT/CT images were
retrieved to the workstation. The images were loaded in
allocated workflows for either std-SPECT/CT or UF-
SPECT/CT; this method allowed the observers to indi-
vidually adjust the brightness and contrast settings of
the images and fusion of the images if desired. Conse-
quently, the individual observers were not blinded to the
type of SPECT/CT.
For the individual patient, the two acquisition types
(std-SPECT/CT and UF-SPECT/CT) were evaluated on
separate days and the patients were randomly assigned
to either std-SPECT/CT (including WB-BS) or UF-
SPECT/CT (including WB-BS) at the first evaluation
day. In order to prevent the observers from recalling the
individual patient, the interval between reading days was
at least 4 weeks. After individual assessment of the im-
ages, consensus was reached between the two observers
in cases of disagreement; there was no need for a third
party arbitrator in any case. If the individual observer
considered the image quality to be inadequate, they were
given the opportunity to deem the investigation or part
of the investigation as “not of diagnostic quality”.
Diagnostic classification
The observers classified each std-SPECT/CT and UF-
SPECT/CT result separately into one of three categories:
(1) normal findings or findings considered to represent
benign conditions (M0), (2) equivocal findings in which
changes were observed on std-SPECT/CT or UF-
SPECT/CT but could not be categorized as benign or
malignant (Me), or (3) findings of bone metastases (M1).
Furthermore, the observers reported the anatomical
localization of the bone metastases or equivocal lesions.
The skeleton was divided into seven anatomical areas:(a) head; (b) thorax, including the sternum; (c) cervical
and thoracic spine; (d) lumbar spine; (e) pelvis, including
the sacrum; (f ) upper extremities, including the scapulae;
and (g) lower extremities. For each anatomical area, the
number of equivocal or malignant lesions was recorded
as “0,” “1,” or “>1”. This classification was used to deter-
mine whether agreement between the acquisition
methods was based on the same lesions.
Statistics
Agreement was assessed using Cohen’s kappa (κ), which
is calculated as the ratio of the overall percent agree-
ment corrected for chance to the maximum possible
percent agreement corrected for chance. We used the
linear weighted κ, and disagreements were ranked ac-
cording to the distance between the categories (e.g., a
disagreement from “0” to “>1” was assigned greater
weight than a disagreement from “0” to “1”). Further-
more, maximum achievable kappa values (κmax) given
the marginal distributions are reported, to determine
how much of the marginally permitted agreement is
present between raters [13]. The magnitude of agree-
ment was classified as slight (kappa 0–0.20), fair (0.21–
0.40), moderate (0.41–0.60), substantial (0.61–0.80), or
almost perfect agreement (0.80–1.0) in accordance with
standardized criteria [14]. Additionally, the Bhapkar test
was performed to assess marginal homogeneity, i.e., to
test if raters have different propensities to use each rat-
ing category. The null hypothesis for Bhapkar’s test is
that marginal probabilities are homogeneous; χ2(degrees
of freedom) and p values are reported. All results are re-
ported with 95% confidence intervals (95% CI), and the
significance level was set to 0.05.
Ethics
This study complied with the Helsinki II Declaration.
The study protocol was assessed by the North Denmark
Region Committee on Health Research Ethics and the
Danish Data Protection Agency. All patients provided
signed informed consent to participate.
Results
Patients
A total of 104 patients (30 women and 74 men, aged
69 ± 10 years) were recruited for this study. The
majority of the included patients had prostate cancer
(n = 71, 68%) or breast cancer (n = 28, 27%), and five
(5%) patients suffered from other cancer types or sev-
eral cancer types. A total of 48 patients (all with
prostate cancer) were referred for staging, 26 patients
were referred due to bone-related pain, 18 patients
were referred because biomarker (PSA or alkaline
phosphate) findings indicated bone metastases, and 12
patients were referred for various other reasons.
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The technical quality of std-SPECT, UF-SPECT, and
low-dose CT was classified as sufficient for diagnostic
purposes by all readers for all patients. Examples of pa-
tients with malignant and benign findings are shown in
Figs. 1 and 2. Std-SPECT/CT showed bone metastases
(M1) in 19 (18%) patients, no bone metastases (M0) in
71 (68%) patients, and equivocal results for bone metas-
tasis in the remaining 14 (14%) patients.
Agreement between std-SPECT/CT and UF-SPECT/CT
Uniform agreement between the consensus diagnosis
(M1, M0, and Me) using UF-SPECT/CT and the consen-
sus diagnosis using std-SPECT/CT was observed in 97
of 104 (93%) patients (Fig. 3). The linear weighted
Cohen’s κ was excellent (κ = 0.91, 95% CI 0.84–0.97;
κmax = 0.93; χ
2(2) = 3.94, p = 0.139). Among the seven pa-
tients with discrepancy between UF and SD SPECT, four
out of seven suspicious/equivocal lesions were in the
pelvic region and three out of seven lesions were in the
thorax region. Thus, no apparent issue with attenuation
mass in the abdomen or pelvis was observed. The agree-
ment between std-SPECT/CT and UF-SPECT/CT was
similar between prostate cancer patients (κ = 0.90, 95%
CI 0.82–0.99; κmax = 0.94; χ
2(2) = 2.41, p = 0.299) and
breast cancer patients (κ = 0.90, 95% CI 0.77–1; κmax =
0.90 χ2(2) = 2.18, p = 0.336). Due to the sample size, no
such calculation was performed for other types of
cancer.
Consensus reading was necessary in 12 of 104 patients
(12%) for UF-SPECT/CT, compared to 15 of 104 pa-
tients (14%) for std-SPECT/CT. In seven patients, con-
sensus reading was necessary for both UF-SPECT/CT
and std-SPECT/CT.
In 102 of 104 patients (98%), there was agreement on
the numbers and localization of the regions of suspi-
cious/malignant lesions using the two SPECT/CT acqui-
sition methods. In one patient, there was disagreementFig. 1 Illustrative examples of the M0 category (no bone metastases); in th
corresponding to benign changes seen on low-dose CT. a Anterior view of
SPECT. b Anterior view of a MIP from standard acquisition SPECTin the number of regions involved, two regions were sus-
picious according to UF-SPECT/CT, but only one of the
regions was considered suspicious by std-SPECT/CT. Fi-
nally, the observers considered suspicious lesions/bone
metastases in completely different regions in one patient
on both std-SPECT/CT and UF-SPECT.Discussion
Timely and accurate diagnosis of bone metastases is crit-
ical to ensure that cancer patients receive the appropri-
ate treatment. WB-BS has been the cornerstone in such
situations for many years. The use of additional SPECT/
CT for evaluating suspicious or equivocal lesions ob-
served on WB-BS has been shown to improve diagnostic
confidence [4, 7, 8, 10], but the resulting increase in ac-
quisition time is undesirable. In the present study, we in-
vestigated the use of UF-SPECT/CT as add-on to WB-
BS for confirming or excluding the presence of bone
metastases in cancer patients, and we found excellent
agreement between UF-SPECT/CT and std-SPECT/CT
for this task. The conclusion of this study is that UF-
SPECT/CT is suitable for clinical practice.
This study included patients with different types of
cancer, although the majority of the patients presented
with prostate or breast cancer. Bone metastases from
prostate and breast cancer differ in terms of morph-
ology: the metastases from prostate cancer are largely
osteosclerotic, and those from breast cancer are a mix-
ture of osteolytic and osteosclerotic. For this reason, the
agreement between UF-SPECT/CT and std-SPECT/CT
was separately assessed for prostate cancer and breast
cancer. There were no clinically relevant differences in
the diagnostic classification between UF-SPECT/CT and
std-SPECT/CT among prostate and breast cancer pa-
tients. This result demonstrates the applicability of UF-
SPECT/CT independent of the presumed histology of
the lesion.is example, tracer uptake was increased in the right side of L5
a maximum intensity projection (MIP) from ultra-fast acquisition
Fig. 2 Illustrative examples of the M1 category (bone metastases); in this example, tracer uptake was increased in the os sacrum and proximal
right femur corresponding to osteosclerotic lesions on low-dose CT. Additionally, tracer uptake was increased in the left side of L3 and L5
corresponding to benign changes seen on low-dose CT. a Posterior view of a maximum intensity projection (MIP) from ultra-fast acquisition
SPECT. b Posterior view of a MIP from standard acquisition SPECT
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to reflect the clinical reality, in which WB-BS, with or
without SPECT/CT, cannot distinguish whether a lesion is
malignant or benign with certainty in all patients. Large
studies performing WB-BS on prostate cancer patients
have revealed that 16–26% of these patients show equivo-
cal WB-BS findings [15, 16]. Previous studies performing
SPECT/CT to evaluate bone metastasis have inconsist-
ently reported the frequency of equivocal scan results. We
have previously shown that there is a need for an equivo-
cal category in the reading of bone scans to avoid0
10
20
30
40
50
60
70
Std-SPECT/CT:                   M0 (n=71)                                  
n=70, 
99%
n=0, 
0%
n=4
29%n=1,
1%
Fig. 3 Consensus diagnosis by two physicians using std-SPECT/CT accordin
served on BS that could not be categorized as benign or malignant; and M
UF-SPECT/CT is showndiagnostic misclassification [17]; we encourage the inclu-
sion of this category for the classification of SPECT/CT
images of the bone, as well. The number of categories in-
creases the options available to observers and thereby de-
creases interobserver agreement. Even though the findings
were categorized into three classes rather than two (M1 or
M0), the interobserver agreement was very satisfactory. In
the present study, 14% of the patients showed equivocal
std-SPECT/CT findings. This percentage might appear ra-
ther high, but in the present study, SPECT/CT was only
conducted as add-on on patients for whom WB-BS wasM0 as determined by UF-SEPCT/CT
Me as determined by UF-SPECT/CT
M1 as determined by UF-SPECT/CT
Me (n=14)             M1 (n=19)
n=17, 
89%
n=2, 
11%
n=10, 
71%
, 
n=0, 
0%
n=0, 
0%
g to a three-category scale: M0: no bone metastasis; Me: changes ob-
1: bone metastases. For each category, the consensus diagnosis for
Zacho et al. EJNMMI Research  (2017) 7:1 Page 6 of 7not entirely diagnostic. Under these conditions, SPECT/
CT provided a definitive classification in 90 of 104 cases.
The excellent agreement between the two acquisition
types in the present study was emphasized by the identi-
fication of suspicious/malignant lesions in identical re-
gions and numbers by the observers in the vast majority
of the patients.
The observers were not blinded to the type of SPECT/
CT. The UF-SPECT/CT images were significantly less
smooth than the std-SPECT/CT images. It could be ar-
gued that the observers’ knowledge of the modality in
which they were interpreting was a weakness of the
present study. To hinder observers from recalling spe-
cific patients at least 4 weeks were interposed between
the evaluation of std-SPECT/CT and the evaluation of
UF-SPECT/CT. Despite the grainy appearance of the
UF-SPECT/CT images, all images were considered by the
observers to be of diagnostic quality and to be supportive
of an inconclusive WB-BS result. An explanation for our
findings could be that the UF-SPECT/CT—in the majority
of cases—was used for anatomical co-registration of suspi-
cious lesions seen on the WB-BS, and for this purpose,
less smooth images appear to be sufficient.
Recently, there has been growing interest in the use of
checklists in diagnostic test accuracy studies, such as
STARD to describe the competencies of the observers, as
their interpretation directly affects the performance of the
diagnostic test [18–20]. We used observers from two dif-
ferent departments of nuclear medicine, one institution
that had slight experience with UF-SPECT/CT and one
without such experience. Evaluation of new modalities by
several observers from different departments is an import-
ant factor to consider when determining whether a new
method is widely applicable. The excellent agreement in
the present study indicates that UF-SPECT/CT can be in-
troduced in departments familiar with std-SPECT/CT
without previous training in UF-SPECT/CT.
For the present study, identical reconstruction algorithms
using iterative reconstruction with resolution recovery were
applied to std-SPECT/CT and UF-SPECT/CT. Aldridge
et al. have investigated the use of different reconstruction
algorithms in parathyroid and bone SPECT/CT. They
found that the use of 3D resolution recovery for image re-
construction resulted in a 50% decrease in acquisition time
without reducing image quality. The use of a 75% reduction
in acquisition time was also investigated, and no reduction
in image quality was observed compared to filtered back
projection [21]. Our results are supported by Stansfield
et al. who investigated image quality in half-time SPECT in
pediatric patients undergoing BS. They found negligible
differences in image quality, noise reduction, and image
sharpness between full- and half-time SPECT [22].
Thientunyakit et al. investigated the use of half-time
SPECT (no CT) compared to multiplanar imaging of thepelvis in patients with significant bladder artifacts on WB-
BS. They concluded that the use of half-time SPECT in-
creased the diagnostic confidence compared to multiplanar
imaging and that the half-time SPECT images were of diag-
nostic quality [22]. Reduction of acquisition time has par-
ticularly been investigated for myocardial perfusion imaging
using SPECT. In general, those studies reported that the
use of alternative acquisition or reconstruction algorithms
compensated for the loss of image quality resulting from a
reduced scan time. No change in reconstruction algorithms
was used in the present study, and the image quality was
not assessed specifically.
Despite that, SPECT/CT has been widely accessible for
more than a decade; studies have hitherto focused on half-
time SPECT. In the present study, the std-SPECT was in
fact a half-time SPECT compared to SPECT with filtered
back projection and the UF-SPECT method used in the
present study reduced acquisition time to 25%. Such short
acquisition times have not been investigated before, pos-
sibly due to concerns regarding reduced image quality.
However, none of the UF-SPECT/CT images was deemed
unsuitable for diagnosis, even though the short-duration
acquisition produced coarser images. On the other hand,
the short acquisition time may be considered more com-
fortable to patients, and consequently, the patients might
be less likely to move during the acquisition period.
For the future studies to optimize SPECT acquisition
balancing image quality versus time, we await that list
mode data becomes available on modern SPECT systems
enabling the user to parse the data and create acquisitions
with any proportion of counts from the full-time dataset,
with no extra scans needed for the patient. Even without
list mode data, this can be achieved by acquiring the
SPECT as a gated dataset (i.e., with ECG trigger), and re-
construction of only a proportion of the time-bins.
Conclusions
In conclusion, UF-SPECT/CT can replace std-SPECT/
CT as add-on to WB-BS for the evaluation of incon-
clusive lesions observed on WB-BS regardless of the
cancer type. Using UF-SPECT/CT, the SPECT acquisi-
tion time can be reduced by 75% without compromis-
ing diagnostic confidence.
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